We partner with a wide range of local and international companies to advance research across the biomedical sciences. These include partnerships with leading Pharmaceutical companies aimed at identifying new therapeutics for neurological disease, oncology and pain. We also perform contract research studies with Industry partners to test therapeutics and develop new approaches to tackle human disease.

Some of our past and ongoing partnerships include Pfizer, Takeda, Grünenthal, and CSL Behring.

We also educate undergraduate and post-graduate students in drug development and biomedical research translation. These themes provide our students with Industry-valued skills that can be used in the future workforce.

Industry news

Landmark deal for UQ-Trinity inflammation startup (Inflazome, September 2020)

Grünenthal and UniQuest partner to develop novel drug candidates for chronic neuropathic pain (Grünenthal, September 2019)

High profile alliance targets potential cancer treatment (Pfizer, June 2019)

Startup raises $63M to advance development of drugs for inflammatory diseases (Inflazome, November 2018)

Takeda announces COCKPI-T Australia 2018 research grants (Takeda, November 2018) 

UQ shines spotlight on research excellence (Alsonex, September 2017) 

New trial may revolutionise treatment of spinal cord injury patients (CSL Behring, January 2017)